GARD-HIPEC
Phase NA Unknown
92 enrolled
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Unknown
45 enrolled
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Phase 2 Unknown
15 enrolled
SUROVA
Unknown
5,000 enrolled
Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study
Unknown
1,000 enrolled
Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
Phase 2 Unknown
34 enrolled
Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
Unknown
20 enrolled
OutCoME
Unknown
75 enrolled
Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy
Phase 2 Unknown
110 enrolled
Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Phase 2 Unknown
96 enrolled
ctDNA Methylation for Epithelial Ovarian Cancer
Unknown
5,000 enrolled
ctDNA Methylation for Detecting Ovarian Cancer
Unknown
1,400 enrolled
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
Phase 2 Unknown
20 enrolled
BOLD
Phase 2 Unknown
74 enrolled
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
Phase 4 Unknown
396 enrolled
VitD
Phase NA Unknown
54 enrolled
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Phase 2 Unknown
20 enrolled
t
Phase 2 Unknown
35 enrolled
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Phase 2 Unknown
35 enrolled
Chromosomal Instability in Ovarian Cancer
Unknown
300 enrolled
HRD and Resistance to PAPPi in EOC Patients
Unknown
400 enrolled
POLO
Phase 4 Unknown
102 enrolled
ORION-02
Phase 1/2 Unknown
31 enrolled
Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer
Phase 3 Unknown
50 enrolled
CLIO
Phase 2 Unknown
160 enrolled
A Training Set for the HRD Model in EOC
Unknown
200 enrolled
Cell-free DNA Methylation for Epithelial Ovarian Cancer
Phase 2 Unknown
400 enrolled
AVANIRA3
Phase 2 Unknown
32 enrolled
ANLOLA
Phase 2 Unknown
68 enrolled
TAILOR
Unknown
48 enrolled
Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE)
Phase NA Unknown
35 enrolled
A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation
Phase 3 Unknown
280 enrolled
68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings
Phase 2 Unknown
30 enrolled
HIPECOV
Phase 3 Unknown
112 enrolled
Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
Phase 4 Unknown
30 enrolled
Genetic Mutation in Epithelial Ovarian Cancer
Unknown
500 enrolled
Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer
Unknown
1,300 enrolled
EHTASEOCCS
Phase 3 Unknown
310 enrolled
HIPOVA-01
Phase 3 Unknown
132 enrolled
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
Phase 3 Unknown
200 enrolled
A Genomic Analysis of Evolution of Epithelia Ovarian Tumors
Unknown
40 enrolled
A Multi-omics Study of Epithelial Ovarian Cancer
Unknown
80 enrolled
Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Unknown
1,000 enrolled
Long-acting G-CSF for Febrile Neutropenia
Phase 3 Unknown
556 enrolled
Ovaire01
Unknown
376 enrolled
hipecova
Phase 3 Unknown
60 enrolled
EHNPCTASEOC
Phase 3 Unknown
263 enrolled
Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer
Unknown
750 enrolled
Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma
Phase 2 Unknown
30 enrolled
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Phase 1/2 Unknown
50 enrolled